Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

Autor: Aditya Lele, Maureen T. Kelly, Christie M. Ballantyne, Carolyn M. Setze, Kamlesh M. Thakker, James C. Stolzenbach, Peter B. Jones
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Male
Simvastatin
genetic structures
Atorvastatin
Pharmacology
Gastroenterology
chemistry.chemical_compound
Fenofibrate
Pharmacology (medical)
Drug Interactions
Rosuvastatin Calcium
Hypertriglyceridemia
Sulfonamides
Anticholesteremic Agents
General Medicine
Middle Aged
lipids (amino acids
peptides
and proteins)
Drug Therapy
Combination
Female
Cardiology and Cardiovascular Medicine
medicine.drug
medicine.medical_specialty
Statin
medicine.drug_class
Article
Fenofibric acid
Pharmacotherapy
Double-Blind Method
Internal medicine
medicine
Humans
Pyrroles
Triglycerides
Apolipoproteins B
Cholesterol
business.industry
nutritional and metabolic diseases
Cholesterol
LDL
medicine.disease
Fluorobenzenes
Pyrimidines
chemistry
Dyslipidemia
Heptanoic Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Zdroj: Cardiovascular Drugs and Therapy
ISSN: 1573-7241
0920-3206
Popis: Objective The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia. Methods This is a post hoc analysis of a subset of patients (N = 92) with mixed dyslipidemia treated with moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for 12 weeks in three controlled trials who had achieved LDL-C 200 mg/dL, and had fenofibric acid 135 mg added to the moderate-dose statin in a 52-week open-label extension study. Lipid and apolipoprotein (Apo) values and the proportion of patients meeting individual and combined treatment targets with combination therapy were determined at scheduled visits during the 52-week study and compared with baseline (start of extension study). Results Addition of fenofibric acid to moderate-dose statin for 52 weeks resulted in significant (P 200 mg/dL led to additional improvements in non–HDL-C, ApoB, HDL-C, and triglycerides that resulted in greater proportions of patients attaining optimal levels of the individual parameters as well as simultaneously achieving optimal levels of these parameters and LDL-C.
Databáze: OpenAIRE
Externí odkaz: